Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Grit AndersenGrégory MeiffrenDaniela LamersJ Hans DeVriesAymeric RansonCyril SeroussiBertrand AlluisMartin GaudierOlivier SoulaTim HeisePublished in: Diabetes, obesity & metabolism (2018)
BCLIS was well tolerated and safe over 14 days of treatment and significantly improved postprandial BG vs LIS when administered at mealtime.